Enanta Pharmaceuticals (ENTA) versus Its Rivals Critical Comparison

Enanta Pharmaceuticals (NASDAQ: ENTA) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Enanta Pharmaceuticals to related businesses based on the strength of its institutional ownership, risk, valuation, earnings, profitability, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Enanta Pharmaceuticals and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enanta Pharmaceuticals 0 1 3 0 2.75
Enanta Pharmaceuticals Competitors 464 2210 6102 117 2.66

Enanta Pharmaceuticals currently has a consensus price target of $42.33, suggesting a potential downside of 12.89%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 2.16%. Given Enanta Pharmaceuticals’ competitors higher probable upside, analysts clearly believe Enanta Pharmaceuticals has less favorable growth aspects than its competitors.

Risk & Volatility

Enanta Pharmaceuticals has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals’ competitors have a beta of 1.63, suggesting that their average share price is 63% more volatile than the S&P 500.

Profitability

This table compares Enanta Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enanta Pharmaceuticals -51.85% -7.74% -7.39%
Enanta Pharmaceuticals Competitors -3,989.00% -119.24% -44.05%

Earnings & Valuation

This table compares Enanta Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Enanta Pharmaceuticals $39.73 million -$30.75 million -45.42
Enanta Pharmaceuticals Competitors $207.80 million -$2.20 million 0.00

Enanta Pharmaceuticals’ competitors have higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

66.1% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 48.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 9.3% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply